Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of <i>ROS1</i> fusion–positive non-small cell lung cancer
A 3-tier reporting system for ROS-1 SP384 IHC testing combining previous interpretation criteria and diffuse and homogeneous immunoreactivity may better predict ROS1 fusion status without decreasing specificity.
Authors
- Hee Sang Hwang (ORCID: https://orcid.org/0000-0001-9486-9214)
- Se Jin Jang (ORCID: https://orcid.org/0000-0001-8239-4362)
- Bokyung Ahn (ORCID: https://orcid.org/0000-0002-0229-2276)
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1093/ajcp/aqae118
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Asan Institute for Life Sciences, Asan Medical Center